Youcare Pharmaceutical (SH:688658) 智通财经网·2025-12-30 00:13Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. (悦康药业) is a biopharmaceutical company focused on the research, development, production, and commercialization of therapies including oligonucleotides, mRNA vaccines, peptides, and innovative traditional Chinese medicine [4] - The company leverages its commercial product portfolio, cross-modal R&D technology platform, GMP-certified production system, and nationwide commercialization network to advance differentiated innovation pipelines in major therapeutic areas with unmet needs and long-term growth potential [4] - Key products include Yuyuan Tong® (Ginkgo biloba extract injection) for managing cerebrovascular and peripheral vascular disorders, Ailishi® (Citrate of Aildenafil tablets) for treating male erectile dysfunction, and other significant products like Liweike® (Omeprazole enteric-coated capsules) and Yuedaning® (Metformin sustained-release tablets) [4] Financial Performance - The company reported revenues of approximately RMB 4.52 billion, RMB 4.18 billion, RMB 3.77 billion, and RMB 1.30 billion for the fiscal years ending December 31, 2022, December 31, 2023, and 2024, and for the seven months ending July 31, 2025, respectively [10] - Gross profit figures were approximately RMB 2.87 billion, RMB 2.58 billion, RMB 2.15 billion, and RMB 596 million for the same periods, with corresponding gross profit margins of 63.5%, 61.6%, 56.9%, and 45.7% [12] - The company incurred a net loss of approximately RMB 146 million for the seven months ending July 31, 2025, primarily due to decreased revenue from cardiovascular products and significant investments in marketing and R&D activities [11] Industry Overview - The global and Chinese pharmaceutical markets are expected to continue expanding from 2020 to 2024, driven by increasing medical demand, a growing burden of chronic diseases, and ongoing improvements in drug innovation and access [13] - The top five therapeutic areas by revenue in 2024 globally will include digestive and metabolic, oncology, systemic anti-infectives, nervous system, and respiratory [14] - The cardiovascular drug market is projected to grow from USD 87.3 billion in 2020 to USD 106.5 billion in 2024, with a compound annual growth rate (CAGR) of 5.1%, expected to reach USD 165.5 billion by 2035 [19]